214 related articles for article (PubMed ID: 8683314)
21. Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course.
Kolesnikov-Gauthier H; Vanlemmens L; Baranzelli MC; Vennin P; Servent V; Fournier C; Carpentier P; Bonneterre J
Breast Cancer Res Treat; 2012 Jan; 131(2):517-25. PubMed ID: 22037787
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings.
Crowe JP; Adler LP; Shenk RR; Sunshine J
Ann Surg Oncol; 1994 Mar; 1(2):132-40. PubMed ID: 7834438
[TBL] [Abstract][Full Text] [Related]
23. FDG PET for detection and therapy control of metastatic germ cell tumor.
Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
[TBL] [Abstract][Full Text] [Related]
24. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
25. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions.
Walter C; Scheidhauer K; Scharl A; Goering UJ; Theissen P; Kugel H; Krahe T; Pietrzyk U
Eur Radiol; 2003 Jul; 13(7):1651-6. PubMed ID: 12835981
[TBL] [Abstract][Full Text] [Related]
26. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
[TBL] [Abstract][Full Text] [Related]
27. Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid.
Leboeuf R; Bénard F; Langlois MF
Clin Nucl Med; 2006 Jul; 31(7):382-5. PubMed ID: 16785803
[TBL] [Abstract][Full Text] [Related]
28. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328
[TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
Smith IC; Welch AE; Hutcheon AW; Miller ID; Payne S; Chilcott F; Waikar S; Whitaker T; Ah-See AK; Eremin O; Heys SD; Gilbert FJ; Sharp PF
J Clin Oncol; 2000 Apr; 18(8):1676-88. PubMed ID: 10764428
[TBL] [Abstract][Full Text] [Related]
30. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.
van Ginkel RJ; Hoekstra HJ; Pruim J; Nieweg OE; Molenaar WM; Paans AM; Willemsen AT; Vaalburg W; Koops HS
J Nucl Med; 1996 Jun; 37(6):984-90. PubMed ID: 8683328
[TBL] [Abstract][Full Text] [Related]
31. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I
Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
[TBL] [Abstract][Full Text] [Related]
32. Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
Jacobs MA; Ouwerkerk R; Wolff AC; Gabrielson E; Warzecha H; Jeter S; Bluemke DA; Wahl R; Stearns V
Breast Cancer Res Treat; 2011 Jul; 128(1):119-26. PubMed ID: 21455671
[TBL] [Abstract][Full Text] [Related]
33. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
Rousseau C; Devillers A; Sagan C; Ferrer L; Bridji B; Campion L; Ricaud M; Bourbouloux E; Doutriaux I; Clouet M; Berton-Rigaud D; Bouriel C; Delecroix V; Garin E; Rouquette S; Resche I; Kerbrat P; Chatal JF; Campone M
J Clin Oncol; 2006 Dec; 24(34):5366-72. PubMed ID: 17088570
[TBL] [Abstract][Full Text] [Related]
34. Lung tumor metastasis to breast detected by fluorine-18-fluorodeoxyglucose PET.
Hunter GJ; Choi NC; McLoud TC; Fischman AJ
J Nucl Med; 1993 Sep; 34(9):1571-3. PubMed ID: 8394885
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
36. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms.
Kitagawa Y; Sadato N; Azuma H; Ogasawara T; Yoshida M; Ishii Y; Yonekura Y
J Nucl Med; 1999 Jul; 40(7):1132-7. PubMed ID: 10405132
[TBL] [Abstract][Full Text] [Related]
37. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas.
Laubenbacher C; Saumweber D; Wagner-Manslau C; Kau RJ; Herz M; Avril N; Ziegler S; Kruschke C; Arnold W; Schwaiger M
J Nucl Med; 1995 Oct; 36(10):1747-57. PubMed ID: 7562038
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography of glucose metabolism in breast cancer. Potential for tumor detection, staging, and evaluation of chemotherapy.
Nieweg OE; Wong WH; Singletary SE; Hortobagyi GN; Kim EE
Ann N Y Acad Sci; 1993 Nov; 698():423-8. PubMed ID: 8279782
[No Abstract] [Full Text] [Related]
39. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
40. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
